Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail shows promise against tough esophageal cancer

NCT ID NCT06010303

Disease control Sponsor: BeiGene Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding an experimental drug called LBL-007 to standard immunotherapy and chemotherapy helps shrink tumors better in people with advanced esophageal cancer that cannot be surgically removed. About 118 participants received either the three-drug combo or the standard two-drug combo as their first treatment. The main goal was to see how many patients had their tumors shrink significantly.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LBL-007 (Alcestobart) plus tislelizumab and chemotherapy
What this could lead to
If successful, this combination could become a new first-line treatment option that shrinks tumors more effectively in people with advanced esophageal cancer.
What could go wrong
This is a Phase 2 trial with only 118 participants, so results are preliminary. The added drug may not improve outcomes and could increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

118 people

The number who actually took part.

Started

Nov 2023

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to provide written informed consent and can agree to comply with the study requirements. * Participants with metastatic ESCC or unresectable, locally advanced ESCC. * Histologically confirmed diagnosis of ESCC. * Can provide a tumor sample. * At least 1 measurable lesion as defined by RECIST v1.1. * Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1. Exclusion Criteria: * Prior treatment for advanced or metastatic ESCC within the past 6 months * Locally advanced ESCC that is either resectable or potentially curable with definitive chemoradiation treatment per local investigator * Palliative radiation treatment for ESCC within the past 4 weeks * Participants with an esophageal/bronchial or esophageal/aorta fistula * Prior treatment with programmed cell death protein-1 (PD-1) or other immune-oncological drugs Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Esophageal cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms esophageal squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Esophageal cancer Esophageal squamous cell carcinoma Esophageal squamous cell carcinoma by ajcc V8 stage

Contacts and locations

Locations

  • Anhui Provincial Hospital

    Hefei, Anhui, 230000, China

  • Anyang Cancer Hospital

    Anyang, Henan, 455001, China

  • Changhua Christian Hospital

    Changhua, 50006, Taiwan

  • China Medical University Hospital

    Taichung, 40447, Taiwan

  • Chonnam National University Hwasun Hospital

    HwasunGun, Jeollanam-do, 58128, South Korea

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350014, China

  • Fujian Medical University Union Hospital

    Fuzhou, Fujian, 350001, China

  • General Hospital of Ningxia Medical University

    Yinchuan, Ningxia, 750004, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, 150000, China

  • Henan Cancer Hospital

    Zhengzhou, Henan, 450000, China

  • Hrh Princess Maha Chakri Sirindhorn Medical Center (Srinakharinwirot University)

    Ongkharak, 26120, Thailand

  • Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

  • Kaohsiung Medical University Chung Ho Memorial Hospital

    Kaohsiung City, 807, Taiwan

  • Lanzhou University Second Hospital

    Lanzhou, Gansu, 730030, China

  • Nanjing Drum Tower Hospital,the Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, 210008, China

  • Nantong Tumor Hospital Branch North

    Nantong, Jiangsu, 226000, China

  • Nanyang Central Hospital

    Nanyang, Henan, 473000, China

  • National Cancer Center

    Goyang-si, Gyeonggi-do, 10408, South Korea

  • National Taiwan University Hospital

    Taipei, 10048, Taiwan

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

  • Phramongkutklao Hospital

    Ratchathewi, 10400, Thailand

  • Ramathibodi Hospital Mahidol University

    Bangkok, 10400, Thailand

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi, 03080, South Korea

  • Severance Hospital Yonsei University Health System

    Seoul, Seoul Teugbyeolsi, 03722, South Korea

  • Shandong Cancer Hospital

    Jinan, Shandong, 250117, China

  • Sichuan Academy of Medical Sciences and Sichuan Provincial Peoples Hospital

    Chengdu, Sichuan, 610071, China

  • Sichuan Cancer Hospital and Institute

    Chengdu, Sichuan, 610041, China

  • Siriraj Hospital

    Bangkok, 10700, Thailand

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, 221000, China

  • The Catholic University of Korea, Seoul St Marys Hospital

    Seoul, Seoul Teugbyeolsi, 06591, South Korea

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, 230000, China

  • The First Affiliated Hospital of Xinxiang Medical University

    Xinxiang, Henan, 453100, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450052, China

  • The First Peoples Hospital of Changzhou

    Changzhou, Jiangsu, 213000, China

  • The Second Affiliated Hospital of Shandong First Medical University

    Taian, Shandong, 271099, China

  • The Tumor Hospital Affiliated to Guangxi Medical University

    Nanning, Guangxi, 530021, China

  • Tianjin Medical University Cancer Institute and Hospital

    Tianjin, Tianjin Municipality, 300060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.